Targeting cGAS-STING Mediated Innate Immune Signaling Breaks the Senescence-Metabolism Vicious Loop in Aged Cardiac Progenitor Cells

Hypothesis

Aged cardiac progenitor cells (CPCs) accumulate mitochondrial DNA damage that activates the cytosolic DNA sensing pathway cGAS‑STING, driving a chronic type‑I interferon response that amplifies the senescence‑associated secretory phenotype (SASP) and locks cells into a glycolytic, low‑ATP state. We hypothesize that pharmacological inhibition of STING will simultaneously reduce SASP secretion, restore mitochondrial oxidative phosphorylation, and re‑enable differentiation of aged CPCs into cardiomyocyte lineages.

Mechanistic rationale

1. Mitochondrial DNA damage → cGAS‑STING activation

   • mtDNA lesions increase in aged CPCs (2) and can escape to the cytosol, where they bind cGAS, producing 2′‑3′‑cGAMP and stimulating STING (4).
   • STING signaling drives IRF3‑dependent IFN‑β production, which has been shown to reinforce p16^INK4a^ expression and SASP in other senescent cell types.

2. STING‑driven IFN signaling amplifies SASP

   • Chronic IFN‑β signaling upregulates secreted IL‑6, IL‑8, and MCP‑1, creating a paracrine loop that induces senescence in neighboring CPCs (3).
   • This loop explains the observed ~60% SA‑β‑gal positivity in aged CPCs versus ~35% in young cells (1).

3. Metabolic consequence

   • IFN‑β signaling suppresses PGC‑1α transcription, reducing mitochondrial biogenesis and forcing reliance on glycolysis, which limits ATP production needed for differentiation (1).
   • Consequently, aged CPCs fail to upregulate OXPHOS complexes upon cardiogenic stimulation.

Testable predictions

• In vitro: Treating aged CPCs from 24‑month mice with the STING inhibitor C‑176 (or siRNA against STING) will: a. Decrease phospho‑STING and IFN‑β levels (ELISA/qPCR). b. Lower SA‑β‑gal, p16, and γ‑H2AX positivity by ≥30%. c. Increase OCR (oxygen consumption rate) and ATP production, restoring OXPHOS complex I‑V levels. d. Enhance expression of cardiac differentiation markers (cTnT, α‑actinin) after BMP/FGF stimulation.

• Ex vivo: Injecting STING‑inhibited aged CPCs into infarcted murine hearts will result in greater engraftment, reduced fibrosis, and improved ejection fraction compared with untreated aged CPCs.

• In vivo: Aged mice receiving systemic STING inhibition (e.g., C‑176) will show a reduction in circulating SASP factors and a partial rescue of endogenous CPC proliferative capacity (Ki‑67^+ c‑Kit^+ cells).

Falsifiability

If STING inhibition fails to reduce SASP markers, does not improve mitochondrial respiration, or does not enhance differentiation capacity under the conditions above, the hypothesis would be refuted. Conversely, a positive outcome would support the notion that breaking the cGAS‑STING‑SASP axis is a viable strategy to rejuvenate aged CPCs, complementing senolytic or metabolic rescue approaches.

Broader impact

This hypothesis integrates the intrinsic mitochondrial defect, the extrinsic senescence loop, and the metabolic paralysis observed in aged CPCs, offering a single nodal point (STING) that could be targeted to simultaneously address multiple hallmarks of cardiac progenitor aging.

References (inline citations already provided in the text).